Skip to content

Effect of transcutaneous auricular vagus nerve stimulation on postoperative depression in patients with breast cancer and preoperative depressive symptoms: a prospective, randomized controlled study

Effect of transcutaneous auricular vagus nerve stimulation on postoperative depression in patients with breast cancer and preoperative depressive symptoms: a prospective, randomized controlled study

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2600118521
Enrollment
Unknown
Registered
2026-02-06
Start date
2026-04-02
Completion date
Unknown
Last updated
2026-02-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Depression

Interventions

taVNS group:Percutaneous auricular vagus nerve stimulation (taVNS), using the instrument model tVN501, with a frequency of 20Hz, a pulse width of 500µs, and a current intensity of 4-6mA, lasts for 30
Control group:False stimulation involves only a 30-second phase of current increase and a 30-second phase of current decrease during each treatment, without continuous stimulation

Sponsors

The First Affiliated Hospital of Anhui Medical University
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. Aged between 18 and 65; 2. ASA Grade I-III; 3. Mild to severe depressive symptoms (11 points < MADRS < 35 points); 4. Female patients scheduled for unilateral radical mastectomy under general anesthesia; 5. Aware of, agreeing to participate in the trial and signing the written informed consent form.

Exclusion criteria

Exclusion criteria: 1. There were severe disorders of heart, lung, liver and kidney functions before the operation; 2. Preoperative radiotherapy or endocrine therapy patients and those undergoing secondary surgery (recurrence or reconstruction); 3. There is a history of mental illness, bipolar disorder or recurrent depression before the operation; 4. Screen for a history of antidepressant treatment or long-term use of psychotropic drugs, long-term use of analgesic drugs, or alcohol abuse within 2 weeks prior to the screening; 5. Inability to cooperate with the researcher for any reason: such as hearing or vision impairment, language comprehension disorder, mental illness, etc; 6. Electronic devices cannot be implanted; 7. Pregnant or lactating women; 8. Participated in other clinical studies in the past three months.

Design outcomes

Primary

MeasureTime frame
Proportion of patients with postoperative depression achieving response (=50% reduction in MADRS score from baseline);

Secondary

MeasureTime frame
MADRS Score;Proportion of patients with postoperative depression achieving remission (MADRS score =11);GAD-7 Score;PSQI Score;QoR-15 Score;Postoperative NRS Pain Score;Length of Stay (LOS);

Countries

China

Contacts

Public ContactChen Lijian

The First Affiliated Hospital of Anhui Medical University

chenlijian77@126.com+86 139 6669 9467

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 15, 2026